ImmVira Partners with Merz Aesthetics to Develop Anti-Wrinkle Exosome Products
Shenzhen-based ImmVira’s exosomes-focused subsidiary has struck a partnership with US leading firm Merz Aesthetics. The...
SciWind Bio and Verdiva Bio Partner on Global Development of Obesity Therapies
On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement...
MediLink and Zai Lab Collaborate on LRRC15-Targeted ADC Drug ZL-6201
Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688)...
Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study
Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for...
Inmagene Biopharmaceuticals Posts Positive Results for IMG-007 in Atopic Dermatitis
Inmagene Biopharmaceuticals, a Sino-US biotech that recently merged with US-based Ikena Oncology, Inc. (NASDAQ: IKNA),...
BrainAurora Medical Technology IPOs on Hong Kong Stock Exchange
Zhejiang-based BrainAurora Medical Technology Limited (HKG: 6681), the first company in China to combine neuroscience...
NMPA Releases 89th Batch of Reference Drugs for GQCE Work
The National Medical Products Administration (NMPA) has released the 89th batch of reference drugs for...
China’s NHC Aims for Over 90% Child-Friendly Hospitals by 2030
The Department of Maternal and Child Health Care of the National Healthcare Commission (NHC) has...
Stryker to Acquire Inari Medical for USD 4.9 Billion to Boost VTE Pipeline
US-based Stryker (NYSE: SYK) has reached a definitive acquisition agreement with compatriot firm Inari Medical,...
GSK Launches Cabotegravir Injection in China for HIV Pre-Exposure Prophylaxis
UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection...
Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in...
Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS
Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS...
NHSA Revises 2024 NRDL Drug Information Based on Public Feedback
China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs...
Eli Lilly China’s Neuroscience VP Jiang Yifei Departs for New Opportunities
Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has...
Fourier Intelligence Secures USD 109 Million in Series E Funding for Robotics Innovation
China-based Shanghai Fourier Intelligence Co., Ltd, a leading developer of exoskeleton robotic products for rehabilitation...
Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...
HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy
Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines...
China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia
China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition...
Huahai Pharmaceutical to Transfer Rights to Innovative Antidepressant HHT001 via Public Listing
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is set to transfer the patent and...
Mabwell’s 9MW2821 Granted Breakthrough Therapy Designation by CDE for Urothelial Carcinoma
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that the Center for Drug...